<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263741</url>
  </required_header>
  <id_info>
    <org_study_id>AHQU-2017002</org_study_id>
    <nct_id>NCT03263741</nct_id>
  </id_info>
  <brief_title>Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer</brief_title>
  <official_title>Exploratory Study on the Efficiency and Safety of Paclitaxel + S-1 + Oxaliplatin Chemotherapy in the Patients With Locally Advanced or Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Hospital of Qinghai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Hospital of Qinghai University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the Efficiency and Safety of Paclitaxel + S-1 + Oxaliplatin (PSOX) Chemotherapy in
      the Patients with Locally Advanced or Advanced Gastric Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the Efficiency and safety of Paclitaxel + S-1 + Oxaliplatin(PSOX) in the Patients
      with Locally Advanced or Advanced Gastric Cancer
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>The sum of complete remission (CR) rate and partial remission (PR) rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>2 years</time_frame>
    <description>From date of enrollment until the date of death from any cause, assessed up to 60 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + S-1 + Oxaliplatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel: 175 mg/m2, iv, 3h, at D1 ; S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + S-1 + Oxaliplatin</intervention_name>
    <description>Paclitaxel: 175 mg/m2, iv, 3h, at D1 S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
Oxaliplatin: 85 mg/m2, iv, 2h, at D1</description>
    <arm_group_label>Paclitaxel + S-1 + Oxaliplatin group</arm_group_label>
    <other_name>Paclitaxel + S-1 + Oxaliplatin chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathology or cytopathology proven gastric cancer or gastroesophageal
             adenocarcinoma;

          2. Locally advanced, or recurrent, or metastasis disease；

          3. Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy
             completed;

          4. Life expectancy of at least 3 months;

          5. ECOG score 0-1;

          6. Age: 18~70 years old;

          7. Normal hemodynamic indices before the recruitment (including blood cell count and
             liver/kidney function). For example: WBC&gt;4.0×109/L, NEU &gt;1.5×109/L, PLT&gt;100×109/L,
             BIL&lt;1.5 times of upper limit of normal reference value, ALT and AST&lt;2.5 times of upper
             limit of normal reference value, and CRE&lt;1.2mg/dl;

          8. Good cardiac function before the recruitment, no seizure of myocardial infarction in
             past half year, and controllable hypertension and other coronary heart diseases;

          9. Not concomitant with other uncontrollable benign diseases before the recruitment (e.g.
             the infection in the lung, kidney and liver);

         10. Not participating in other study projects before and during the treatment;

         11. Voluntarily signed the informed consent.

        Exclusion Criteria:

          1. Previously treated with first-line chemotherapy;

          2. Allergy to the drugs in this protocol;

          3. Pregnant or lactating women;

          4. Women at childbearing age and of pregnancy desire during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiuda Zhao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Hospital of Qinghai University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiuda Zhao, M.D.</last_name>
    <phone>+8613327661976</phone>
    <email>jiudazhao@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of Qinghai University</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <zip>810000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiuda Zhao, M.D.</last_name>
      <phone>+8613327661976</phone>
      <email>jiudazhao@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Dengfeng Ren, M.D.</last_name>
      <phone>+8613086297659</phone>
      <email>dengfeng1104@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Hospital of Qinghai University</investigator_affiliation>
    <investigator_full_name>Jiuda Zhao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Paclitaxel</keyword>
  <keyword>S-1</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Efficiency</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

